Date: 2015-02-18
Type of information: Licensing agreement
Compound: GS Xceed™ System
Company: Argen-X (Belgium) Lonza (Switzerland)
Therapeutic area: Technology - Services
Type agreement: licensing production manufacturing
Action mechanism:
Disease:
Details: * On February 18, 2015, Lonza and arGEN-X announced that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. The license secures long-term access for arGEN-X and its strategic partners to Lonza’s proprietary GS Xceed™ System for creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals. The GS Xceed™ license agreement builds upon the productive relationship between Lonza and arGEN-X. Lonza has manufactured two of arGEN-X’s clinical-stage proprietary therapeutic antibodies to date, as well as a third program due to commence clinical trials in 2015. Under the new agreement, arGEN-X has access to the GS Xceed™ System for the development and manufacture of both current and future therapeutic antibody products.
Financial terms:
Latest news:
